Form 4: Zenas BioPharma Director Patrick Enright Reports Conversion of Preferred Stock and Option Grant Following IPO

Director Patrick G. Enright reports the conversion of Series B and C Convertible Preferred Stock into common stock and the acquisition of stock options following Zenas BioPharma's IPO.

Summary

• Patrick G. Enright, a director of Zenas BioPharma, filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
• The filing reports the automatic conversion of Series B and Series C Convertible Preferred Stock into common stock on September 16, 2024, upon the closing of Zenas BioPharma's initial public offering (IPO).
• The Series B Convertible Preferred Stock converted on an 8.6831-for-1 basis, resulting in Enright acquiring 723,812 shares of common stock.
• Similarly, the Series C Convertible Preferred Stock converted on an 8.6831-for-1 basis, resulting in Enright acquiring 1,003,592 and 334,530 shares of common stock.
• Enright also reported the purchase of 440,000 shares of common stock at a price of $17 per share.
• Additionally, Enright was granted an option to buy 37,000 shares of common stock at an exercise price of $17, vesting in equal annual installments over three years starting September 12, 2025.
• The shares are indirectly held through Longitude Venture Partners IV, L.P. (LVPIV) and Longitude Prime Fund, L.P. (LPF).
• Longitude Capital Partners IV, LLC (LCPIV) and Longitude Prime Partners, LLC (LPP) are the general partners of LVPIV and LPF, respectively, and may be deemed to have voting, investment, and dispositive power over these securities.
• Juliet Tammenoms Bakker and Patrick G. Enright, as managing members of LCPIV and LPP, may also be deemed to share voting, investment, and dispositive power.

Sentiment

Score: 7

Explanation: The document reflects standard insider activity following an IPO, with conversions of preferred stock and option grants. The director's purchase of shares at $17 is a positive signal.

Positives

• The conversion of preferred stock to common stock simplifies the capital structure of Zenas BioPharma following its IPO.
• The option grant incentivizes Enright to continue contributing to the company's success.
• Enright's purchase of 440,000 shares at $17 shows confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice for company insiders to report changes in their ownership of company securities, providing transparency to investors.

Comparison to Industry Standards

• Form 4 filings are a regulatory requirement for insiders of publicly traded companies in the United States, ensuring transparency and preventing insider trading.
• The reporting requirements are standardized across all companies listed on U.S. exchanges, including companies like Amgen, Biogen, and Gilead Sciences.

Stakeholder Impact

• The conversion of preferred stock to common stock may dilute existing shareholders' ownership.
• The option grant could potentially increase the number of shares outstanding in the future.

Key Dates